Nausicalm Enfants (Dimenhydrinate)

Dimenhydrinate, the active ingredient in Nausicalm Enfants, is a first‑generation antihistamine presented as an oral formulation for pediatric use. It is employed to prevent and treat motion‑induced nausea and vomiting, as well as nausea associated with vertigo, in children.

GNH USA supplies Nausicalm Enfants as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Dimenhydrinate acts on vestibular and central pathways that trigger nausea and vomiting in children. - Motion sickness: prevents and treats motion‑induced nausea and vomiting in pediatric patients. - Vertigo‑related nausea: reduces nausea and vomiting associated with vestibular disturbances. - General pediatric nausea: alleviates acute nausea and vomiting of various causes in children.

Dimenhydrinate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness - Dry mouth - Blurred vision - Constipation

Serious or Rare Side Effects: - Allergic reactions such as rash, swelling, or anaphylaxis - Cardiac arrhythmias - Severe sedation leading to accidents or respiratory depression

When using Dimenhydrinate in children, several safety considerations are recommended. - Assess age and weight: verify appropriate pediatric dosing before administration. - Hypersensitivity: avoid in children with known allergy to dimenhydrinate or other first‑generation antihistamines. - Respiratory conditions: use caution in children with asthma or chronic bronchial disease. - Sedation monitoring: observe for excessive drowsiness, especially if combined with other CNS depressants. - Store at room temperature: keep in the original container, protect from moisture and light.

Dimenhydrinate can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent first‑generation antihistamines: increased anticholinergic load. - Sedatives or alcohol: profound central nervous system depression. - Monoamine oxidase inhibitors: risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - Other anticholinergic agents (e.g., atropine): additive anticholinergic effects. - Antipsychotics such as phenothiazines: enhanced sedation. - Tricyclic antidepressants: increased anticholinergic side effects.